GMC Cancer Lead
Mark is a Consultant Haematologist at University Hospitals Birmingham, specialising in plasma cell disorders and stem cell transplant, delivering one of the busiest plasma cell disorders practices in the UK. He is currently Trust Lead Cancer Clinician and Associate Director of Research responsible for cancer at UHB, responsible for ensuring functionality at an MDT (multidisciplinary team) to deliver high quality outcomes across all tumour sites. Mark is also responsible for supporting the delivery of world class research for patients with cancer.
Mark believes research is fundamental to the delivery of high quality care. He is vice-chair of the Myeloma Research Alliance which designs and delivers clinical trials in the UK for patients with myeloma. He has been Chief Investigator and Principal Investigator on several national clinical trials. Mark is Co-Chief Investigator with Professor Kwee Yong for the forthcoming national study Myeloma XV.
As Cancer Lead for the West Midlands Genomic Medicine Centre Mark is completely aligned with the strategy of developing a lasting infrastructure to deliver genomic medicine both during the lifetime of the 100,000 Genomes Project and after the project concludes. He is part of the group that will be delivering digital pathology across the regional footprint of the GMC. Mark’s current focus is Genomic Tumour Advisory Boards – the mechanism by which complex genomic information is integrated into the decision-making process to inform and improve patient treatment and outcomes.